当前位置：
X-MOL 学术
›
Nat. Rev. Neurosci.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The future of stem cell therapies for Parkinson disease.
Nature Reviews Neuroscience ( IF 28.7 ) Pub Date : 2020-01-06 , DOI: 10.1038/s41583-019-0257-7 Malin Parmar 1, 2 , Shane Grealish 1, 2 , Claire Henchcliffe 3
Nature Reviews Neuroscience ( IF 28.7 ) Pub Date : 2020-01-06 , DOI: 10.1038/s41583-019-0257-7 Malin Parmar 1, 2 , Shane Grealish 1, 2 , Claire Henchcliffe 3
Affiliation
|
Cell-replacement therapies have long been an attractive prospect for treating Parkinson disease. However, the outcomes of fetal tissue-derived cell transplants in individuals with Parkinson disease have been variable, in part owing to the limitations of fetal tissue as a cell source, relating to its availability and the lack of possibility for standardization and to variation in methods. Advances in developmental and stem cell biology have allowed the development of cell-replacement therapies that comprise dopamine neurons derived from human pluripotent stem cells, which have several advantages over fetal cell-derived therapies. In this Review, we critically assess the potential trajectory of this line of translational and clinical research and address its possibilities and current limitations and the broader range of Parkinson disease features that dopamine cell replacement based on generating neurons from human pluripotent stem cells could effectively treat in the future.
中文翻译：
帕金森病干细胞疗法的未来。
长期以来，细胞置换疗法一直是治疗帕金森氏病的诱人前景。然而，帕金森氏病患者胎儿组织来源的细胞移植的结果是可变的，部分是由于胎儿组织作为细胞来源的局限性，涉及其可用性，缺乏标准化的可能性以及方法的变化。发展和干细胞生物学的进步已允许开发包含人类多能干细胞衍生的多巴胺神经元的细胞替代疗法，与胎儿细胞衍生疗法相比，它具有若干优势。在这篇评论中，
更新日期：2020-01-06
中文翻译：
帕金森病干细胞疗法的未来。
长期以来，细胞置换疗法一直是治疗帕金森氏病的诱人前景。然而，帕金森氏病患者胎儿组织来源的细胞移植的结果是可变的，部分是由于胎儿组织作为细胞来源的局限性，涉及其可用性，缺乏标准化的可能性以及方法的变化。发展和干细胞生物学的进步已允许开发包含人类多能干细胞衍生的多巴胺神经元的细胞替代疗法，与胎儿细胞衍生疗法相比，它具有若干优势。在这篇评论中，
京公网安备 11010802027423号